Syndromic Multiplex Diagnostic Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Syndromic Multiplex Diagnostic Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The Syndromic Multiplex Diagnostic Market is expected to grow at a CAGR of 7.2 % over the forecast period (2022-2027).

Covid-19 has a considerable effect on all major organ systems. Due to the rising number of cases of Covid-19 in the early stages of the pandemic, all hospitals around the world canceled medical visits and the target population remained indoors fearing the infection. Covid-19 affected diagnostics procedures widely, including labor force and staffing difficulties, procedural prioritizing, and intraoperative viral transmission risk. However, the use of multiplex diagnostic panels during the pandemic has increased in hospitals for early and rapid detection of Covid-19 in critically ill respiratory patients. The research and developments increased for the development of advanced diagnostic solutions for the detection of SARS-CoV-2. Major players focused more on innovations and increased investments in developing devices or panels for multiplexed detection of the virus. For instance, in March 2021, ArcDia International Ltd launched a range of exceptionally sensitive point-of-care rapid tests for Covid-19, and the mariPOC analyzer developed is easy to operate and enables high-throughput, quick, and automated COVID-19 antigen testing. Therefore, the pandemic is anticipated to significantly impact the market studied.

Factors such as increasing demand for accurate and rapid results and quick access to the treatment and reduction of the adverse reactions of antibiotics are expected to positively impact the market growth.

The market is driven by the fact that the global burden of diseases has increased in recent years. This created a higher demand for accurate and rapid test results and is driven due to the rapid spread of infections along with the launch of new products. For instance, the World Health Organization (WHO) report updated in September 2021 stated that more than 55 million people live with dementia worldwide, and there are nearly 10 million new cases every year, with Alzheimer's disease (AD) accounting for most of the cases. To detect such rare diseases several multiplex panels have been developed. For instance, the article “Advances in multiplex PCR for Alzheimer's disease diagnostics targeting CDK genes” published in April 2021 stated that the researchers of the study developed a multiplex-PCR (polymerase chain reaction) based diagnostic method, which showed the rapid and accurate detection of AD biomarkers. Such developments and research are increasing the demand for syndromic multiplex diagnostics, thereby driving the market growth.

In addition, the Australian Federation of AIDS Organizations (AFAO) estimated that around 29,090 people are estimated to be living with Human immunodeficiency virus infection (HIV), and 2,610 people are unaware they are positive in 2020. Western blotting is the gold-standard test for the detection of HIV. For this, the demand for multiplex syndromic testing is increasing with the increase in cases of various diseases. Thus, the growing burden of such diseases is demanding more accurate and rapid test results, and it is expected to propel the studied market growth over the forecast period.

Furthermore, there is an increasing demand for accurate and rapid results globally. For instance, in October 2021, Hologic launched Novodiag System in Europe. Novodiag is a fully automated molecular diagnostic solution for on-demand testing of infectious diseases and antimicrobial resistance. Additionally, in July 2021, QuantuMDx launched its Q-POC, a rapid, PCR point of care diagnostic system. QuantuMDx’s Q-POC system and its first test, a SARS-CoV-2 detection assay, also received CE-IVD marking under the In Vitro Diagnostics Directive and enable use within Europe. Such developments are anticipated to fuel market growth.

Therefore, owing to the above-mentioned factors the market studied is expected to grow over the forecast period. However, the lack of skilled professionals and the inability in detecting asymptomatic cases are the factors that are anticipated to hinder the market growth.

The advantages of syndromic panels for gastrointestinal (GI) illnesses are similar to respiratory syndromic panels. They quickly identify a wide spectrum of GI pathogens with great sensitivity and specificity. As there is a lot of clinical overlap between pathogens that cause GI disease, GI syndromic panels are very useful.

Additionally, overall, syndromic testing in GI promises comprehensive testing as well as considerably reduced turnaround times, enhanced sensitivity, increased pathogen identification, and streamlined ordering techniques, all of which are aimed at improving clinical outcomes. The shortened workflow that results has a significant impact on lab efficiency. For instance, the data updated by BioFire Diagnostics in 2022 shows that the BioFire FilmArray GI Panel is a quick polymerase chain reaction (PCR) test that identifies 22 most common pathogens associated with gastroenteritis from a single patient sample, including 13 bacteria, 5 viruses, and 4 parasites, with findings available in about 1 hour. Such advantages of technologically advanced panels developed for GI diseases, is anticipated to drive segment growth.

Moreover, the recent developments and advancements in the segment are increasing recently. For instance, in January 2022, Qiagen has expanded the menu of its QIAstat-Dx syndromic testing system and expects to release QIAstat-Dx Rise, a higher throughput version of the device, later in 2022. The ability to distinguish between gastrointestinal pathogens as well as meningitis and encephalitis illnesses has been added to the new QIAstat-Dx menu. Such advancements in the segment are expected to fuel market growth.

Therefore, owing to the factors mentioned above, the segment is anticipated to witness growth over the forecast period.

North America is anticipated to witness growth over the forecast period and dominate the market. Among other countries in the region, United States is leading the market, due to factors such as an increase in healthcare expenditure, increasing research and developments, and a rising prevalence of various communicable or non-communicable diseases. Additionally, the rising geriatric population across United States is the primary driver for United States Syndromic Multiplex Diagnostic Market .​

For instance, the “HIV Government factsheet” last updated in June 2021 shows that in United States, approximately 1.2 million people are infected with human immunodeficiency virus (HIV), and about a third of the target population were unaware that they have HIV and require testing. Thus, the prevalence of infectious diseases in United States demands syndromic multiplex diagnostic testing and is expected to drive market growth over the forecast period.

Moreover, the development activities by the market players in the form of product launches, acquisitions, mergers, and investments are also expected to enhance the market growth. For example, in January 2022, QIAGEN, a major player in the studied market, based in United States reported significant advancements in the commercialization of its QIAstat-Dx syndromic testing solution, which enables laboratories and hospitals to test patients for multiple pathogens from one sample. The application for United States regulatory approval of a Gastrointestinal (GI) panel that can detect 22 common viral, bacterial, and parasite pathogens that can cause potentially fatal diseases.

In addition, in December 2021, Applied BioCode received Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) for its BioCode CoV-2 Flu Plus Assay. This PCR-based, multiplex molecular diagnostic assay can simultaneously detect and differentiate between SARS-CoV-2, Influenza A with subtypes (seasonal H1, 2009 H1N1, H3, Influenza B), and Respiratory Syncytial Virus (RSV) in nasopharyngeal swab specimens. In addition to United States, Canada is one of the major countries which is focused on recent advances in the syndromic multiplex diagnostics segment. For instance, in January 2022, Seegene Inc. South Korean molecular diagnostic company received approval for its Allplex SARS CoV-2 FluA/FluB/RSV Assay under Health Canada's Interim Order. The Allplex SARS CoV-2 FluA/FluB/RSV Assay from Seegene is a multiplex real-time PCR assay that allows for both amplification and differentiation of respiratory symptoms. It can distinguish between Influenza A, B, RSV, and COVID-19 in a single test. These increasing developments in the market across all the countries in North America are anticipated to drive market growth over the forecast period in the country.

Therefore, owing to the factors mentioned above, North America is predicted to be the major market for syndromic multiplex diagnostics, which is expected to witness growth over the forecast period.

The global Syndromic Multiplex Diagnostic Market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are launching new products, while others are distributing the products, making acquisitions and partnerships to increase their footprints in the market. Some of the companies which are currently dominating the market are BIOMERIEUX, DiaSorin S.p.A (Luminex Corporation), QIAGEN, Applied BioCode, and Akonni Biosystems.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support